IBIO Latest Press Releases

-- July 1, 2026 --

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study Globe Newswire 7:00 AM

-- June 2, 2026 --

iBio to Participate in Upcoming Healthcare Investor Conferences Globe Newswire 4:01 PM

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity Globe Newswire 7:00 AM

-- May 12, 2026 --

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update Globe Newswire 4:05 PM

-- May 8, 2026 --

iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors Globe Newswire 7:15 AM

-- April 8, 2026 --

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia Globe Newswire 7:00 AM

-- March 16, 2026 --

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) Globe Newswire 4:30 PM

-- March 9, 2026 --

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss Globe Newswire 7:00 AM

-- February 24, 2026 --

iBio to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software